Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.
The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5918
The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.
Segmentation
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).
On the basis of diagnosis, the Global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.
On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.
On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.
Regional Analysis
The global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.
Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.
The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of this market.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918
About Us:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]
